| Fully human anti CD19 CAR-T Cell Therapy (University Hospitals Cleveland Medical Center) |
|
Phase 1 Clinical |
University Hospitals Cleveland Medical Center |
Precursor Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Non-Hodgkin; Leukemia, Lymphocytic, Chronic, B-Cell |
Details
|
| Anti-CD20 CAR T-cell therapy (Southwest Hospital Chongqing) |
|
Phase 2 Clinical |
Southwest Hospital Chongqing |
Lymphoma, Large B-Cell, Diffuse |
Details
|
| aCD19z |
aCD19z |
Phase 1 Clinical |
Christie Hospital Nhs Foundation Trust |
Lymphoma, Non-Hodgkin |
Details
|
| PTG-01 |
PTG-01 |
Phase 1 Clinical |
Protheragen |
Precursor Cell Lymphoblastic Leukemia-Lymphoma |
Details
|
| H-31970-SAGAN |
H-31970-SAGAN |
Phase 1 Clinical |
Baylor College Of Medicine |
Precursor Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Non-Hodgkin; Leukemia, Lymphocytic, Chronic, B-Cell |
Details
|
| Anti-CD19 CAR T-cell therapy (Leidos Biomedical Research) |
|
Clinical |
Leidos |
Lymphoma, Large B-Cell, Diffuse; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Mantle-Cell; Leukemia, Lymphocytic, Chronic, B-Cell |
Details
|
| Virus-specific-CD19.CAR |
|
Phase 1 Clinical |
Baylor College Of Medicine |
Lymphoma, Non-Hodgkin; Leukemia, Lymphocytic, Chronic, B-Cell |
Details
|
| Anti-CD19 CAR T-cell therapy (Southwest Hospital Chongqing) |
|
Phase 2 Clinical |
Southwest Hospital Chongqing |
Lymphoma, Large B-Cell, Diffuse |
Details
|
| CD19.CAR-VST |
CD19.CAR-VST |
Phase 1 Clinical |
Baylor College Of Medicine |
Precursor Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Non-Hodgkin; Leukemia, Lymphocytic, Chronic, B-Cell |
Details
|
| Anti-CD19 CAR T cell therapy (Wuhan Bio-Raid) |
|
Phase 2 Clinical |
Wuhan Bio-Raid Biotechnology |
Hematologic Diseases; Lymphoma, B-Cell |
Details
|
| Anti-CD19 CAR-T cell therapy (Japan Tissue Engineering) |
|
Phase 1 Clinical |
Nagoya University, Shinshu University |
Precursor Cell Lymphoblastic Leukemia-Lymphoma |
Details
|
| 1928-zT-2 (Guangzhou Institutes of Biomedicine and Health) |
|
Phase 1 Clinical |
Guangzhou Institute Of Biomedicine And Health, Chinese Academy Of Sciences |
Precursor Cell Lymphoblastic Leukemia-Lymphoma |
Details
|
| Anti-CD19 CAR T-cell therapy (Shenzhen Institute for Innovation and Translational Medicine) |
yinnuokati-19 |
Phase 2 Clinical |
Dongguan People'S Hospital, Shenzhen Institute For Innovation & Translational Medicine |
Precursor Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma; Leukemia, Lymphocytic, Chronic, B-Cell |
Details
|
| Anti-CD19 CAR T-cell therapy (Nanjing Medical University) |
XLCART-001 |
Phase 2 Clinical |
Nanjing Medical University |
Lymphoma, B-Cell |
Details
|
| Anti-CD19 and anti-CD22 CAR T cell therapy (Seattle Children's Hospital) |
|
Phase 1 Clinical |
Seattle Children'S Hospital |
Precursor Cell Lymphoblastic Leukemia-Lymphoma |
Details
|
| Autologous CD19CAR-CD28-CD3zeta-EGFRt-expressing Tcm-enriched T cells (City of Hope Medical Center) |
|
Phase 1 Clinical |
City Of Hope National Medical Center |
Lymphoma, Non-Hodgkin |
Details
|
| CD19/CD20 dual-target CAR-T cell therapy (Shenzhen University General Hospital) |
|
Phase 2 Clinical |
Shenzhen University General Hospital |
Lymphoma, B-Cell |
Details
|
| Anti-CD19 CAR CIK-cell therapy (Formula Pharmaceuticals) |
CARCIK-CD19; CIK-CAR.CD19 |
Phase 2 Clinical |
Fondazione Matilde Tettamanti Menotti De Marchi Onlus |
Precursor Cell Lymphoblastic Leukemia-Lymphoma |
Details
|
| U-CART (Shanghai Bioray Laboratory Inc) |
|
Phase 2 Clinical |
|
Hematologic Neoplasms; Precursor Cell Lymphoblastic Leukemia-Lymphoma |
Details
|
| Anti-CD19 CAR-T cell therapy (The First Affiliated Hospital of Nanchang University) |
|
Phase 2 Clinical |
The First Affiliated Hospital Of Nanchang University |
Precursor Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma |
Details
|
| Anti-CD19 CAR-T cell therapy (Sinobioway) |
|
Phase 2 Clinical |
Sinobioway Biomedicine Co Ltd |
Lymphoma, Large B-Cell, Diffuse; Lymphoma |
Details
|
| Anti-CD19 single-stranded antibody CAR T-cell therapy (Beijing Yongtai Rec Biotechnology) |
|
Phase 1 Clinical |
Beijing Yongtai Rec Biotechnology Co Ltd |
Precursor Cell Lymphoblastic Leukemia-Lymphoma |
Details
|
| CD19 CAR-T cell therapy (National University of Malaysia) |
|
Phase 3 Clinical |
National University Of Malaysia |
Precursor Cell Lymphoblastic Leukemia-Lymphoma |
Details
|
| CART-19 cells (Henan Hualong Biotechnology) |
|
Phase 2 Clinical |
Henan Hualong Biotechnology |
Leukemia, Lymphoid |
Details
|
| Anti-CD19 CAR-T Cells (Yan'an Affiliated Hospital of Kunming Medical University) |
|
Phase 1 Clinical |
Kunming Medical University |
Lymphoma, B-Cell; Precursor Cell Lymphoblastic Leukemia-Lymphoma |
Details
|
| Anti-CD7 and anti-CD19 chimeric antigen receptor T cell therapy |
GC-197 |
Phase 2 Clinical |
|
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma |
Details
|
| CD19 CAR-T (HuaDao CAR-Tcell) |
|
Phase 1 Clinical |
Huadao (Shanghai) Biopharma Co Ltd |
Lymphoma, B-Cell; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma |
Details
|
| K-193 |
K-193 |
Phase 1 Clinical |
Beijing Lvzhu Biological Technology Co Ltd |
Lymphoma, B-Cell |
Details
|
| CLBR-001/SWI-019 |
CLBR-001/SWI-019 |
Phase 1 Clinical |
Abbvie Inc, California Institute For Biomedical Research |
Lymphoma, B-Cell |
Details
|
| NCAR19-T |
|
Phase 2 Clinical |
Second Military Medical University Of Chinese People'S Liberation Army |
Lymphoma, B-Cell |
Details
|
| 19273-4SCAR |
19273-4SCAR |
Phase 2 Clinical |
Peking University |
Lymphoma, B-Cell |
Details
|
| CD19 PD-1/CD28 CAR-T Cell Therapy (Second Affiliated Hospital School Of Zhejiang University School Of Medicine) |
|
Phase 1 Clinical |
Second Affiliated Hospital Of Zhejiang University School Of Medicine |
Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Follicular; Lymphoma, Mantle-Cell; Primary mediastinal B cell lymphoma |
Details
|
| MCM-998 |
MCM-998; LXG-250 |
Phase 1 Clinical |
Novartis Pharma Ag |
Multiple Myeloma |
Details
|
| CC-312 |
CC-312 |
Phase 1 Clinical |
|
|
Details
|
| Anti-CD19/22-CAR vector-transduced T cell therapy (Chinese PLA General Hospital) |
|
Phase 2 Clinical |
People'S Liberation Army General Hospital Military Service |
Leukemia; Lymphoma |
Details
|
| Anti-CD19 CAR-T cell therapy (iCarTAB BioMed) |
|
Phase 1 Clinical |
|
Leukemia; Lymphoma |
Details
|
| dPD-1 hCD19 CART cell therapy (Innovative Cellular Therapeutics) |
ICTCAR-014 |
Phase 2 Clinical |
Innovative Cellular Therapeutics Co Ltd |
Lymphoma, Non-Hodgkin |
Details
|
| Ensomafusp alfa |
RG-6076 |
Phase 1 Clinical |
F. Hoffmann-La Roche Ltd |
|
Details
|
| CTA-101 |
CTA-101 |
Phase 1 Clinical |
Nanjing Bioheng Biotech Co Ltd, Nanjing Medical University, Xuzhou Medical University (Xzmu) |
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma |
Details
|
| SGN-CD19B |
SGN-CD19B |
|
Seattle Genetics Inc |
|
Details
|
| 19(T2)28z1xx Chimeric Antigen Receptor (CAR) Modified T Cells |
TAK-940 |
|
Takeda |
Neoplasms |
Details
|
| Autologous humanized anti-CD19 and anti-CD20 dual specific CAR-T cell therapy (First Affiliated Hospital of Zhejiang University) |
|
Phase 1 Clinical |
First Affiliated Hospital Of Zhejiang University |
Lymphoma, Large B-Cell, Diffuse |
Details
|
| Anti-human CD19-CD22 T cell therapy |
|
Phase 1 Clinical |
Hrain Biotechnology Co Ltd |
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma |
Details
|
| CD19-CAR-T2 cell therapy (Nanfang Hospital of Southern Medical University) |
|
Phase 2 Clinical |
Nanfang Hospital Of Southern Medical University |
Leukemia, Biphenotypic, Acute |
Details
|
| CD19/CD22 dual-target CAR-T cell therapy (Shenzhen University General Hospital) |
|
Phase 2 Clinical |
Shenzhen University General Hospital |
Precursor Cell Lymphoblastic Leukemia-Lymphoma |
Details
|
| Anbalcabtagene autoleucel |
CRC-01 |
|
Curocell Inc |
|
Details
|
| RGV-004 |
RGV-004 |
Phase 1 Clinical |
Hangzhou Rongu Biotechnology Co Ltd |
Lymphoma, B-Cell |
Details
|
| Anti-CD19 and anti-CD22 CAR-T cell therapy(IASO Biotherapeutics) |
CT-120 |
Phase 2 Clinical |
Nanjing Iaso Biotherapeutics Co Ltd |
Lymphoma, B-Cell; Leukemia, B-Cell; Lymphoma, Non-Hodgkin |
Details
|
| Obecabtagene autoleucel |
AUTO1; Obe-cel; AUTO-1 |
|
University College London |
|
Details
|
| CD19x22 CAR T Cell Therapy (University Of Colorado Denver) |
|
Phase 1 Clinical |
University Of Colorado, Denver, Usa |
Lymphoma, Non-Hodgkin |
Details
|
| GC-502 |
GC-502 |
|
|
|
Details
|
| ALLO-501A |
ALLO-501A |
|
Allogene Therapeutics Inc |
|
Details
|
| Allogeneic CD-19 CAR-T Cell Therapy |
|
|
Shenzhen University General Hospital |
|
Details
|
| CD19-CART (Express 4-1BB, Unicar-Therapy Bio-medicine Technology) |
|
|
|
|
Details
|
| IMJ-995 |
IMJ-995 |
|
Novartis Pharma Ag |
|
Details
|
| SNUH-CD19-CAR-T Cell Therapy |
SNUH-CD19-CAR-T |
|
Seoul National University Hospital |
|
Details
|
| CD19-UCART |
CD-19-UCART; CD19-UCART |
Phase 1 Clinical |
Bioray Laboraytories Inc |
Precursor Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Non-Hodgkin |
Details
|
| BinD-19 (Shenzhen BinDeBio) |
BinD-19 |
|
Shenzhen Bindebio Ltd |
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma |
Details
|
| CD19-CART (Unicar-Therapy Bio-medicine Technology) |
|
|
|
|
Details
|
| YTB-323 |
YTB-323 |
Phase 2 Clinical |
Novartis Pharma Ag |
Lymphoma, Large B-Cell, Diffuse |
Details
|
| CD19-CART (IL-6 secretion knockdown, Unicar-Therapy Bio-medicine Technology) |
ssCART-19 |
Phase 1 Clinical |
|
Precursor Cell Lymphoblastic Leukemia-Lymphoma; Leukemia, B-Cell |
Details
|
| BCMA/CD19 CAR-T cell therapy (The First Affiliated Hospital of Nanchang University) |
|
|
The First Affiliated Hospital Of Nanchang University |
|
Details
|
| Autologous CD19-directed chimeric antigen receptor (CAR) T-cell therapy (University of Alberta) |
|
|
University Of Alberta |
|
Details
|
| Anti-CD19 CAR T-cell therapy (University College London) |
4G7-CARD |
|
University College London |
|
Details
|
| Anti-CD19 CAR T cell therapy (Shanghai GeneChem) |
|
|
Shanghai Genechem Co Ltd |
|
Details
|
| XYF19 CAR-T Cell Therapy |
XYF-19 |
|
Xi'An Yufan Biotechnology Co Ltd |
|
Details
|
| Humanized anti-CD19 and anti-CD20 dual specific CAR-T cell therapy (Fujian Medical University) |
|
|
Fujian Medical University |
|
Details
|
| pCAR-19B |
|
Phase 2 Clinical |
Chongqing Precision Biotechnology Co Ltd |
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Precursor Cell Lymphoblastic Leukemia-Lymphoma |
Details
|
| AFM-11 |
AFM-11 |
|
Affimed |
|
Details
|
| Anti-CD19 CAR T-cell therapy (Sheba Medical Center) |
|
|
Chaim Sheba Medical Center At Tel Hashomer |
|
Details
|
| MDX 1342 |
MDX-1342 |
|
Medarex |
|
Details
|
| CAR-T 19 cell therapy (University of Pennsylvania) |
|
|
University Of Pennsylvania |
|
Details
|
| A-319 |
A-319 |
Phase 1 Clinical |
Evive Biotech Ltd |
Lymphoma, B-Cell; Leukemia, B-Cell |
Details
|
| IKS-03 |
IKS-03 |
Phase 1 Clinical |
Iksuda Therapeutics |
Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Follicular; Lymphoma, Mantle-Cell |
Details
|
| CD19 CAR engineered autologous T-cells Therapy(Sabz Biomedicals) |
|
Phase 1 Clinical |
Sabz Biomedicals |
Leukemia, Biphenotypic, Acute |
Details
|
| CD19-targeted chimeric antigen receptor T-cell(Pell Bio-Med Technology) |
PL-001 |
Phase 2 Clinical |
Pell Bio-Med Technology Co Ltd |
Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Follicular; Primary mediastinal B cell lymphoma |
Details
|
| TNB-486 |
TNB-486 |
Phase 1 Clinical |
Teneobio Inc |
Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Follicular; Lymphoma, Non-Hodgkin |
Details
|
| bispecific CD19/CD22 CAR T-cell therapy （University of Colorado） |
|
Phase 1 Clinical |
University Of Colorado |
Lymphoma, B-Cell; Lymphoma, Non-Hodgkin |
Details
|
| ICT19G1 |
ICT-19G1 |
Phase 1 Clinical |
Innovative Cellular Therapeutics Co Ltd |
Precursor Cell Lymphoblastic Leukemia-Lymphoma |
Details
|
| CD19 chimeric antigen receptor T cell therapy (Takara Bio) |
TBI-1501 |
Phase 2 Clinical |
Memorial Sloan Kettering Cancer Center, Takara Bio Inc |
Precursor Cell Lymphoblastic Leukemia-Lymphoma |
Details
|
| Senl-1904A |
Senl-1904A; Senl_1904A |
Phase 1 Clinical |
Hebei Senlang Biological Technology Co Ltd |
Precursor Cell Lymphoblastic Leukemia-Lymphoma |
Details
|
| MC-19PD1 CAR-T cell therapy (Peking University) |
|
Phase 1 Clinical |
Peking University |
Lymphoma |
Details
|
| CD19 UCAR-T cell therapy (Shanghai Longyao Biotechnology) |
|
Phase 1 Clinical |
Shanghai Longyao Biological Technology Co Ltd |
Leukemia, Myeloid, Acute |
Details
|
| Anti-CD19 CAR-T cells therapy (Tianjin Mycure Medical Technology) |
|
Phase 1 Clinical |
Tianjin Mycure Medical Technology Co Ltd |
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma |
Details
|
| Anti-CD19 CAR T-cell therapy (Fujian Medical University) |
|
Phase 3 Clinical |
Fujian Medical University |
Lymphoma, B-Cell |
Details
|
| GNR-084 |
GNR-084 |
Phase 2 Clinical |
Generium Pharmaceuticals, Iontas |
Precursor Cell Lymphoblastic Leukemia-Lymphoma; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma |
Details
|
| CD19-STAR-T cell therapy (China Immunotech Co Ltd) |
|
Phase 1 Clinical |
Hebei Yanda Hospital, China Immunotech Co Ltd |
Lymphoma, B-Cell |
Details
|
| CAR-NK019（Second Affiliated Hospital, School of Medicine, Zhejiang University） |
|
Phase 1 Clinical |
|
Lymphoma, Non-Hodgkin |
Details
|
| CD19/CD22 dual-target CAR-T (Yake biotechnology) |
|
Phase 2 Clinical |
Shanghai YaKe Biotechnology Co Ltd |
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma |
Details
|
| RO-7227166 |
RO-7227166 |
Phase 1 Clinical |
F. Hoffmann-La Roche Ltd |
Lymphoma, Non-Hodgkin |
Details
|
| Anti-CD19 CAR T-cell therapy (Nanjing CART Medical Technology) |
|
Clinical |
Nanjing Kati Medical Technology Co Ltd |
Neoplasms |
Details
|
| BZ019 |
BZ-019 |
Phase 2 Clinical |
Shanghai Cell Therapy Group Co Ltd |
Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Follicular; Primary mediastinal B cell lymphoma; Lymphoma |
Details
|
| Anti-CD22/CD19 monoclonal antibody-toxin conjugate |
|
Phase 1 Clinical |
The University Of Texas Southwestern Medical Center |
Lymphoma, B-Cell; Precursor Cell Lymphoblastic Leukemia-Lymphoma |
Details
|
| CD19-CD22 CAR-T cells (Shanghai Ultra-T Immune Therapeutics) |
|
Phase 2 Clinical |
Shanghai Ultra-T Immune Therapeutics Co LTD |
Lymphoma, B-Cell; Multiple Myeloma; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Leukemia, B-Cell |
Details
|
| ET190L1-ARTEMIS T cells (Eureka Therapeutics) |
ET190L1-ARTEMI; ET-190; ET190L1; ET190 |
Phase 1 Clinical |
Eureka Therapeutics Inc |
Lymphoma, B-Cell; Leukemia, B-Cell |
Details
|
| Anti-CD19 CAR-T cell therapy (Juno Therapeutics) |
|
Phase 1 Clinical |
|
Leukemia, Lymphocytic, Chronic, B-Cell |
Details
|
| Bispecific CD19/22 CAR T cells |
|
Phase 2 Clinical |
|
Lymphoma, Non-Hodgkin; Lymphoma |
Details
|
| 3rd-gen-CD19-CAR |
3rd-gen-CD19-CAR |
Phase 2 Clinical |
Bluebird Bio Inc |
Lymphoma, B-Cell; Leukemia, B-Cell |
Details
|
| FT-819 |
FT-8198; FT-819 |
Phase 1 Clinical |
Fate Therapeutics Inc |
Lymphoma, B-Cell; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Leukemia, Lymphocytic, Chronic, B-Cell |
Details
|
| FT-596 |
FT-596 |
Phase 1 Clinical |
Fate Therapeutics Inc |
Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Non-Hodgkin; Leukemia, Myeloid, Acute; Leukemia, Lymphocytic, Chronic, B-Cell |
Details
|
| 4G7SDIE |
|
Clinical |
Synimmune Gmbh, The University Of Tubingen |
Precursor Cell Lymphoblastic Leukemia-Lymphoma |
Details
|
| U-01 |
U-01 |
Phase 1 Clinical |
Shanghai Unicar-Therapy Bio-Medicine Technology Co Ltd |
Leukemia; Leukemia, B-Cell |
Details
|
| Anti-CD19 CAR-T cell therapy (Pinze Lifetechnologies) |
PZ-01 |
Clinical |
Pinze Lifetechnology Co Ltd |
Lymphoma, B-Cell; Precursor Cell Lymphoblastic Leukemia-Lymphoma |
Details
|
| Anti-CD19 anti-CD22 bispecific chimeric antigen receptor T cell therapy (Hrain Biotechnology) |
|
Phase 1 Clinical |
Hrain Biotechnology Co Ltd |
Leukemia, Lymphoid |
Details
|
| Anti-CD19 chimeric antigen receptor T cell therapy (Immune cell) |
|
Phase 1 Clinical |
Immune Cell Inc |
Lymphoma, B-Cell; Leukemia, B-Cell |
Details
|
| Anti-CD19+/BCMA CAR-T cells (Hrain Biotechnology) |
|
Phase 1 Clinical |
Hrain Biotechnology Co Ltd |
POEMS Syndrome |
Details
|
| Autologous Human Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing CD4+/CD8+ T-lymphocytes (Fred Hutchinson Cancer Research Center) |
|
Phase 1 Clinical |
Fred Hutchinson Cancer Research Center |
Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Primary mediastinal B cell lymphoma; Leukemia, B-Cell; Lymphoma, Non-Hodgkin |
Details
|
| C-CAR039 |
EXP-039; C-CAR039; C-CAR-039 |
Phase 1 Clinical |
|
Lymphoma, Non-Hodgkin |
Details
|
| CAR-20-19-22 |
CAR-20-19-22 |
Phase 1 Clinical |
The Medical College Of Wisconsin Nonprofit |
Lymphoma, Non-Hodgkin; Leukemia, Lymphocytic, Chronic, B-Cell |
Details
|
| CD19/22 Bi-specific CAR-T Cell Therapy(Shenzhen Geno-Immune Medical Institute) |
4SCAR19/22 |
Phase 2 Clinical |
Shenzhen Geno-Immune Medical Institute |
Lymphoma, B-Cell; Leukemia, B-Cell |
Details
|
| CD19/79b Bi-specific CAR-T Cell Therapy (Shenzhen Geno-Immune Medical Institute) |
bi-4SCAR CD19/79b |
Phase 2 Clinical |
Shenzhen Geno-Immune Medical Institute |
Lymphoma, B-Cell |
Details
|
| MB-CART19.1 (Miltenyi Biotec) |
|
Phase 2 Clinical |
Miltenyi Biotec |
Lymphoma, B-Cell; Leukemia, Lymphoid; Precursor Cell Lymphoblastic Leukemia-Lymphoma |
Details
|
| Anti-CD19 CAR-T therapy (Wuhan Sian Medical Technology) |
|
Phase 3 Clinical |
Wuhan Si'an Medical Technology Co Ltd, Xiangyang Central Hospital, Jingzhou Central Hospital, Wuhan Union Hospital, The First People'S Hospital Of Yuhang District |
Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Follicular; Lymphoma, Mantle-Cell; Burkitt Lymphoma; Leukemia, Lymphocytic, Chronic, B-Cell |
Details
|
| HuCART19 |
|
Phase 2 Clinical |
National Cancer Institute |
Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Non-Hodgkin |
Details
|
| Zamtocabtagene autoleucel |
MB-CART2019.1 |
Phase 2 Clinical |
Miltenyi Biotec |
Lymphoma, Large B-Cell, Diffuse |
Details
|
| CD3/CD19 neg allogeneic BMT (National Institute of Allergy and Infectious Diseases/University of Pittsburgh) |
|
Phase 2 Clinical |
National Institute Of Allergy And Infectious Diseases (Niaid), University Of Pittsburgh |
Primary Immunodeficiency Diseases; Female Urogenital Diseases; Inflammation |
Details
|
| Anti-CD19 universal CAR-T cell therapy (Chongqing Xinqiao Hospital) |
|
Phase 1 Clinical |
Xinqiao Hospital, Army Medical University |
Lymphoma, B-Cell; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma |
Details
|
| 4-1BBz CD19-Her2tG (Seattle Children's Hospital) |
|
Phase 1 Clinical |
Seattle Children'S Hospital |
Leukemia; Neoplasms; Lymphoma |
Details
|
| Anti-CD19 CAR-T cell therapy (Shenzhen Geno-Immune Medical Institute) |
4SCAR-19 |
Phase 2 Clinical |
Shenzhen Geno-Immune Medical Institute |
Lymphoma, B-Cell |
Details
|
| Anti-CD19 CAR T-cell therapy (Hrain Biotechnology) |
|
Phase 2 Clinical |
Shanghai Zhongshan Hospital, Hrain Biotechnology Co Ltd |
Candidiasis, Vulvovaginal; Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Follicular; Precursor Cell Lymphoblastic Leukemia-Lymphoma |
Details
|
| CD20-CD19 cCAR T cell therapy (iCell Gene Therapeutics) |
|
Phase 1 Clinical |
|
Lymphoma, B-Cell; Leukemia, B-Cell |
Details
|
| CLIC-1901 (Ottawa Hospital Research Institute) |
CLIC-1901 |
Phase 2 Clinical |
Ottawa Hospital Research Institute |
Precursor Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Non-Hodgkin; Leukemia, Lymphocytic, Chronic, B-Cell |
Details
|
| Chimeric antigen receptor T cell therapeutics (targeted CD19/CD20/CD22/CD30，Shanghai Unicar-Therapy Bio-medicine) |
|
Phase 2 Clinical |
Shanghai Unicar-Therapy Bio-Medicine Technology Co Ltd |
Pancreatic Neoplasms; Lymphoma, Non-Hodgkin |
Details
|
| Anti-CD19 CAR-T cell therapy (Bellicum Pharmaceuticals) |
BPX-401 |
Phase 2 Clinical |
Bellicum Pharmaceuticals Inc, Ospedale Pediatrico Bambino Gesu |
Leukemia; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma |
Details
|
| Anti-CD19 and anti-CD20 CAR-T cell therapy (Medical College of Wisconsin) |
CAR-20/19-T cells |
Phase 2 Clinical |
The Medical College Of Wisconsin Nonprofit |
Lymphoma, B-Cell; Lymphoma, B-Cell, Marginal Zone; Lymphoma, Large B-Cell, Diffuse; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Follicular; Lymphoma, Mantle-Cell; Lymphoma, Non-Hodgkin; Leukemia, Lymphocytic, Chronic, B-Cell |
Details
|
| Murine CD19 CAR-T cell therapy (Yake) |
|
Phase 1 Clinical |
Shanghai YaKe Biotechnology Co Ltd |
Precursor Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Non-Hodgkin |
Details
|
| PBLTT52CAR19 |
|
Phase 1 Clinical |
Great Ormond Street Hospital For Children Nhs Foundation Trust |
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma |
Details
|
| CD19/BCMA-targeted CAR-T Cell Therapy (Zhejiang University) |
|
Phase 1 Clinical |
Zhejiang University |
Nephritis; Sjogren's Syndrome; Scleroderma, Systemic; Autoimmune Diseases; Multiple Myeloma; Lupus Nephritis; Lupus Erythematosus, Systemic; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Non-Hodgkin |
Details
|
| CTA-30X |
CTA30X; CTA-30X |
Phase 1 Clinical |
|
Precursor Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Non-Hodgkin |
Details
|
| CAR-NK-CD19 Cell Therapy (Wuhan Union Hospital) |
|
Phase 1 Clinical |
Wuhan Union Hospital |
Lymphoma, B-Cell; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Leukemia, Lymphocytic, Chronic, B-Cell |
Details
|
| Anti-CD19 CAR-T cell therapy (Zhongyuan Union Cell & Gene Engineering) |
|
Phase 1 Clinical |
Institute Of Hematology & Blood Diseases Hospital |
Lymphoma, B-Cell; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Precursor Cell Lymphoblastic Leukemia-Lymphoma |
Details
|
| CD19/70 Bi-specific CAR-T Cell Therapy (Shenzhen Geno-Immune Medical Institute) |
|
Phase 2 Clinical |
Shenzhen Geno-Immune Medical Institute |
Lymphoma, B-Cell |
Details
|
| CD19-CAR-T cell therapy (China Immunotech Co., Ltd.) |
|
Phase 1 Clinical |
China Immunotech Co Ltd, Hebei Yanda Ludaopei Hospital |
Lymphoma, B-Cell |
Details
|
| Anti-CD19 CAR T-cell therapy (Dana-Farber Cancer Institute/Memorial Sloan-Kettering Cancer Center/Boston Children's Hospital) |
|
Phase 2 Clinical |
Memorial Sloan Kettering Cancer Center, Dana-Farber Cancer Institute, Boston Children'S Hospital |
Leukemia |
Details
|
| Humanized CD19 CAR-T cell therapy (Yake) |
YK-C19 |
Phase 1 Clinical |
Shanghai YaKe Biotechnology Co Ltd |
Lymphoma, B-Cell; Leukemia, Lymphoid; Precursor Cell Lymphoblastic Leukemia-Lymphoma |
Details
|
| CD19 CARvac T cell therapy (iCell Gene Therapeutics) |
|
Phase 1 Clinical |
|
Lymphoma, B-Cell; Leukemia, B-Cell |
Details
|
| Anti CD19 chimeric antigen receptor T cell therapy (YaKe Biotechnology) |
|
Phase 2 Clinical |
Shanghai YaKe Biotechnology Co Ltd |
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Precursor Cell Lymphoblastic Leukemia-Lymphoma |
Details
|
| TG-1801 |
NI-1701; TG-1801 |
Phase 1 Clinical |
Novimmune Sa |
Lymphoma, B-Cell |
Details
|
| Autologous anti-CD19 chimeric antigen receptor T-cell therapy (Malaghan Institute of Medical Research) |
WZTL002-1 |
Phase 1 Clinical |
The Malaghan Institute Of Medical Research |
Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Follicular; Lymphoma, Mantle-Cell; Primary mediastinal B cell lymphoma; Lymphoma, Non-Hodgkin |
Details
|
| CD19/CD20 bispecific CAR-T cells (Henan Cancer Hospital) |
|
Phase 1 Clinical |
Henan Provincial Cancer Hospital |
Lymphoma, B-Cell |
Details
|
| Allogeneic EBV-specific anti-CD19 CAR-T cell therapy (Memorial Sloan-Kettering Cancer Center) |
|
Phase 1 Clinical |
Memorial Sloan Kettering Cancer Center |
Leukemia, Lymphocytic, Chronic, B-Cell |
Details
|
| CTL-119 |
CTL-119 |
Phase 1 Clinical |
Novartis Pharma Ag, University Of Pennsylvania |
Multiple Myeloma |
Details
|
| Anti-CD19/CD22 bispecific CAR-T cell therapy (The Second Affiliated Hospital of Henan University of Traditional Chinese Medicine) |
|
Phase 1 Clinical |
The Second Affiliated Hospital Of Henan University Of Traditional Chinese Medicine |
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma |
Details
|
| Autologous CAR19 T lymphocytes Therapy |
|
Phase 1 Clinical |
Institute of Hematology and Blood Transfusion, Czech Republic |
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Non-Hodgkin |
Details
|
| Autologous hematopoietic stem cell therapy (YaKe Biotechnology) |
|
Phase 1 Clinical |
Zhejiang University |
Lymphoma |
Details
|
| Dual Anti-CD22/CD19 Chimeric Antigen Receptor-directed T Cells (CART2219.1) therapy (KK Women's and Children's Hospital) |
|
Phase 2 Clinical |
Kk Women'S And Children'S Hospital |
Leukemia, Lymphoid; Precursor Cell Lymphoblastic Leukemia-Lymphoma |
Details
|
| CD19/CD20 CAR-T Cell Therapy (PersonGen) |
|
Phase 1 Clinical |
Persongen Biotherapeutics |
|
Details
|
| ALLO-501 |
ALLO-501 |
|
Cellectis Sa |
|
Details
|
| CD19 CAR-T cell therapy (The First Affiliated Hospital of Soochow University) |
|
Phase 2 Clinical |
The First Affiliated Hospital Of Soochow University, Suzhou University |
Leukemia; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma |
Details
|
| Dual anti-CD19/CD22 CAR‐T cell therapy (B-cell malignancies, Stanford University) |
|
Phase 1 Clinical |
Stanford University, Orca Biosystems Inc |
Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Neoplasm, Residual; Leukemia, Lymphoid; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma |
Details
|
| GC019F |
|
Phase 1 Clinical |
Gracell Biotechnologies (Shanghai) Co Ltd |
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Leukemia, B-Cell |
Details
|
| CD19.CAR T Cells (Heidelberg University Hospital) |
|
Phase 2 Clinical |
Heidelberg University Hospital |
Lymphoma, Large B-Cell, Diffuse; Lymphoma, Mantle-Cell; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Follicular; Leukemia, Lymphocytic, Chronic, B-Cell |
Details
|
| GC-022 |
GC-022; GC-022F |
Phase 2 Clinical |
Gracell Biotechnologies (Shanghai) Co Ltd |
Hematologic Neoplasms; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Non-Hodgkin |
Details
|
| CD19-CD123 cCAR T-cells Therapy(iCell Gene Therapeutics) |
ICG140 |
|
iCell Gene Therapeutics LLC |
|
Details
|
| TAK-007 |
TAK-007 |
Phase 2 Clinical |
The University Of Texas MD Anderson Cancer Center |
Lymphoma, Non-Hodgkin |
Details
|
| CD19-CAR-DNT cells Therapy（Zhejiang Ruijiamei Biotechnologies Co Ltd） |
|
Phase 1 Clinical |
Zhejiang Ruijiamei Biotechnologies Co Ltd |
Lymphoma, B-Cell |
Details
|
| Anti-CD19/CD22 CAR-T cell therapy (Jiao Tong University) |
|
Phase 1 Clinical |
Shanghai Jiaotong University, Shanghai General Hospital |
Precursor Cell Lymphoblastic Leukemia-Lymphoma |
Details
|
| Anti-CD19 CAR-T cell therapy (Uppsala University) |
|
Phase 2 Clinical |
Uppsala University |
Lymphoma, B-Cell; Leukemia, B-Cell |
Details
|
| CD19-targeting humanized selective CAR-T cell therapy (Xuanwu Hospital, Beijing) |
|
Phase 2 Clinical |
Xuanwu Hospital Of Capital Medical University |
Precursor Cell Lymphoblastic Leukemia-Lymphoma |
Details
|
| ThisCART-19 |
ThisCART-19; ThisCART19A; ThisCART19C; ThisCART19B |
Phase 1 Clinical |
Fundamenta Therapeutics Ltd |
Lymphoma, B-Cell; Leukemia, Lymphoid; Lymphoma, AIDS-Related; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Burkitt Lymphoma; Lymphoma, Non-Hodgkin; Lymphoma |
Details
|
| Evoncabtagene pazurgedleucel |
CTX-110 |
Phase 1 Clinical |
Crispr Therapeutics Ag |
Lymphoma, B-Cell; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Non-Hodgkin |
Details
|
| Recombinant humanized anti-CD19/CD3 bispecific antibody(New Time Pharmaceutical) |
LNF-1904 |
Phase 1 Clinical |
Shandong New Time Pharmaceutical Co Ltd |
Lymphoma, B-Cell; Leukemia, B-Cell |
Details
|
| Anti-BCMA/CD19 CAR-T Therapy(University College London) |
|
Phase 1 Clinical |
University College London |
Multiple Myeloma |
Details
|
| CD19/CD20 bispecific chimeric antigen receptor (CAR)-T cell therapy (Jonsson Comprehensive Cancer Center) |
|
Phase 1 Clinical |
Uclas Jonsson Comprehensive Cancer Center |
Lymphoma, B-Cell; Leukemia, Lymphoid; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Follicular; Lymphoma, Mantle-Cell; Leukemia, Lymphocytic, Chronic, B-Cell |
Details
|
| Azercabtagene zapreleucel |
PBCAR-0191 |
Phase 2 Clinical |
Baxalta Incorporated |
Hematologic Neoplasms; Leukemia, Lymphoid; Neoplasms; Lymphoma, Non-Hodgkin |
Details
|
| ET-019002 |
ET-019002 |
Phase 1 Clinical |
Eureka Therapeutics Inc |
Lymphoma, B-Cell; Neoplasms |
Details
|
| IM19CAR-T |
|
Phase 2 Clinical |
Beijing Yimiao Medical Technology Co Ltd |
Hematologic Neoplasms; Leukemia; Neoplasms; Lymphoma, Mantle-Cell; Leukemia, B-Cell; Lymphoproliferative Disorders; Lymphoma, Non-Hodgkin; Lymphoma |
Details
|
| CC-97540 |
CC-97540 |
Phase 1 Clinical |
|
Lymphoma, Large B-Cell, Diffuse; Lymphoma, Non-Hodgkin; Lymphoma |
Details
|
| RG-6333 |
RO-7443904 |
Phase 1 Clinical |
F. Hoffmann-La Roche Ag |
Lymphoma, Non-Hodgkin |
Details
|
| 1-A-46 |
1A46; 1-A-46; CMG1A46; CMG1A-46; BR110 |
Phase 2 Clinical |
Chengdu Chimagen Biosciences Co Ltd, Hisun Biopharmaceutical Co Ltd, BioRay Pharmaceutical Co Ltd |
Precursor Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Non-Hodgkin |
Details
|
| Anti-CD19 CAR-Engineered NK Cells therapy (Simnova) |
CAR-NK-CD19 |
Phase 1 Clinical |
Shanghai Simnova Biotechnology Co Ltd |
Precursor Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Non-Hodgkin; Leukemia, Lymphocytic, Chronic, B-Cell |
Details
|
| BCMA-CD19 cCAR T cell therapy (iCell Gene Therapeutics) |
|
Phase 1 Clinical |
Icell Gene Therapeutics (Int'L) Ltd |
Multiple Myeloma; Lupus Erythematosus, Systemic |
Details
|
| GB5005 chimeric antigen receptor T cell therapy (Genbase) |
GB-5005 |
Phase 1 Clinical |
Shanghai Genbase Biotechnology Co Ltd, Shanghai Genechem Co Ltd |
Leukemia, B-Cell |
Details
|
| Anti-CD19 CAR T-cell therapy (Hebei Senlang Biotechnology) |
SENL-B19 |
Phase 2 Clinical |
Hebei Senlang Biological Technology Co Ltd |
Lymphoma, B-Cell; Leukemia; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Leukemia, B-Cell; Lymphoma |
Details
|
| JCAR-014 |
JCAR-014 |
Phase 2 Clinical |
Fred Hutchinson Cancer Research Center, Memorial Sloan Kettering Cancer Center, Seattle Children'S Research Institute, Juno Therapeutics Inc |
Leukemia; Lymphoma, B-Cell; Leukemia, Lymphoid; Lymphoma, Large B-Cell, Diffuse; Hodgkin Disease; Candidiasis; Lymphoma, Mantle-Cell; Primary mediastinal B cell lymphoma; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Leukemia, B-Cell; Lymphoma, Non-Hodgkin; Leukemia, Lymphocytic, Chronic, B-Cell |
Details
|
| CAR-CD19 T cell therapy |
|
Phase 2 Clinical |
|
Lymphoma, Non-Hodgkin |
Details
|
| Anti-CD19 chimeric antigen receptor T cell therapy (Innovative Cellular Therapeutics) |
|
Phase 2 Clinical |
Zhejiang University, Innovative Cellular Therapeutics Co Ltd, Kunming Medical University |
Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Leukemia, B-Cell; Lymphoma |
Details
|
| Anti-CD19 and anti-CD22 CAR T cell therapy (Hebei Senlang Biotechnology) |
|
Phase 1 Clinical |
Hebei Senlang Biological Technology Co Ltd |
Leukemia, B-Cell |
Details
|
| CD19/CD20 Dual CAR-T Cell Therapy (China Immunotech) |
HX-s001; YTS101; HX-s001/YTS101; HXYT-001 |
Phase 1 Clinical |
Beijing Qingyi Taike Pharmaceutical Technology Co Ltd, China Immunotech Co Ltd |
Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Leukemia, B-Cell; Lymphoma, Non-Hodgkin |
Details
|
| KUR-502 CD19 CAR-NKT |
CMD-502; KUR-502 |
Phase 1 Clinical |
Athenex Inc |
Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Leukemia, B-Cell; Lymphoma, Non-Hodgkin; Leukemia, Lymphocytic, Chronic, B-Cell |
Details
|
| CD19/CD20 bispecific CAR-T cells (Shanghai Cellular) |
|
Phase 2 Clinical |
Shanghai Cellular Biopharmaceutical Group Ltd |
Lymphoma, B-Cell |
Details
|
| Anti-CD19-CAR γδT cells (Beijing Doing Biomedical) |
|
Phase 1 Clinical |
|
Leukemia; Lymphoma |
Details
|
| Anti-CD19-CAR T cells (Beijing Doing Biomedical) |
|
Phase 1 Clinical |
|
Leukemia |
Details
|
| Anti-CD19-CAR CMV-specific T-lymphocytes cell therapy (City Of Hope National Medical Center) |
|
Phase 1 Clinical |
City Of Hope National Medical Center |
Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Mantle-Cell; Lymphoma, Non-Hodgkin |
Details
|
| UCART-19 |
S-68587; UCART-19 |
Phase 1 Clinical |
Cellectis Sa |
Leukemia, Lymphoid; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma |
Details
|
| CD19- and CD22 specific CAR (Seattle Children's Hospital) |
|
Phase 1 Clinical |
Seattle Children'S Hospital |
Leukemia; Lymphoma |
Details
|
| CN-201 |
CN-201 |
Phase 2 Clinical |
Tongrun Biomedicine (Shanghai) Co Ltd |
Lymphoma, B-Cell; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Leukemia, B-Cell; Lymphoma, Non-Hodgkin |
Details
|
| ISIKOK-19 |
ISIKOK-19 |
Phase 2 Clinical |
Acibadem University |
Precursor Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Non-Hodgkin |
Details
|
| KYV-101 |
KYV-101 |
Phase 1 Clinical |
National Institutes Of Health, Kyverna Therapeutics Inc |
Lupus Nephritis |
Details
|
| Humanized CAR19T2 T Cell therapy（Zhaotai Cell Bio-tech） |
|
|
|
|
Details
|
| CD19-t-haNK |
|
Phase 1 Clinical |
Nantkwest Inc, Immunitybio Inc |
Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Lymphoma; Lymphoma, Large-Cell, Anaplastic; Lymphoma, Non-Hodgkin |
Details
|
| GC-012F |
GC-012F |
Phase 2 Clinical |
Gracell Biotechnologies (Shanghai) Co Ltd |
Multiple Myeloma; Lymphoma, Non-Hodgkin |
Details
|
| α/β CD3+/CD19+ cell depleted stem cell therapy (Mitchell Cairo) |
|
Phase 2 Clinical |
New York Medical College |
Leukemia; Anemia; Thalassemia; Hodgkin Disease; Anemia, Aplastic; Lymphoma, Non-Hodgkin; Thrombocytopenia; Kostmann Syndrome; Anemia, Sickle Cell |
Details
|
| CD19/CD22 CAR-T cell therapy (Federal Research Institute of Pediatric Hematology, Oncology and Immunology) |
|
Phase 2 Clinical |
|
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Burkitt Lymphoma |
Details
|
| KITE-363 |
KITE-363 |
Phase 1 Clinical |
Kite Pharma |
Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse |
Details
|
| Vadacabtagene leraleucel |
19-28z CAR T cells; 19-28z+ T cells; JCAR-015; JCAR-15; 19-28z-T-Cells |
Phase 1 Clinical |
Juno Therapeutics Inc, Memorial Sloan Kettering Cancer Center, Seattle Children'S Research Institute, Fred Hutchinson Cancer Research Center |
Leukemia; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Non-Hodgkin |
Details
|
| TC-110 |
TC-110 |
Phase 2 Clinical |
Tcr2 Therapeutics Inc |
Lymphoma, Large B-Cell, Diffuse; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Follicular; Lymphoma, Mantle-Cell; Primary mediastinal B cell lymphoma; Lymphoma, Non-Hodgkin |
Details
|
| CD19-TriCAR-T/SILK Cell Therapy(Timmune Biotech) |
|
Phase 1 Clinical |
Tianjin Timmune Biotech Inc |
Leukemia |
Details
|
| iPD1 CD19 eCAR-T therapy (Marino Biotechnology) |
|
Phase 1 Clinical |
Chengdu Yinhe Biomedicine Co Ltd, Beijing Marino Biotechnology Co Ltd |
Lymphoma, B-Cell; Glioblastoma |
Details
|
| TI-1007 |
TI-1007 |
Phase 1 Clinical |
Tianjin Timmune Biotech Inc |
Lymphoma, B-Cell |
Details
|
| CD19 CAR-T cell therapy (Chongqing Precision Biotech) |
|
Phase 2 Clinical |
Chongqing Precision Biotechnology Co Ltd |
Leukemia; Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Leukemia, B-Cell; Lymphoma, Non-Hodgkin; Lymphoma; Leukemia, Lymphocytic, Chronic, B-Cell |
Details
|
| Autologous CD19/CD22 chimeric antigen receptor T-cell therapy (MD Anderson Cancer Center) |
|
Phase 2 Clinical |
The University Of Texas MD Anderson Cancer Center |
Neoplasm, Residual; Leukemia, Lymphoid; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Leukemia, B-Cell; Lymphoma, Non-Hodgkin; Leukemia, Lymphocytic, Chronic, B-Cell |
Details
|
| CNTY-101 |
CNTY-101 |
Phase 1 Clinical |
Century Therapeutics Llc |
Lymphoma, B-Cell; Lymphoma, Non-Hodgkin |
Details
|
| CD19 directed CAR T cell therapy (University of Colorado） |
|
Phase 1 Clinical |
University Of Colorado |
Precursor Cell Lymphoblastic Leukemia-Lymphoma |
Details
|
| Anti-CD19-CAR T cell therapy (Kecellitics Biotech) |
|
Phase 1 Clinical |
Kecellitics Biotech Company Ltd |
Leukemia |
Details
|
| C-CAR011 |
|
Phase 2 Clinical |
Pla General Hospital |
Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Mantle-Cell; Lymphoma |
Details
|
| TanCART19/20 |
|
Phase 1 Clinical |
Pla General Hospital |
Neuromyelitis Optica |
Details
|
| UCART019 |
UCART-019 |
Phase 2 Clinical |
Pla General Hospital |
Lymphoma, B-Cell; Leukemia, B-Cell |
Details
|
| CD19-PD1-CAR T cell therapy (Chinese PLA General Hospital) |
|
Phase 2 Clinical |
Pla General Hospital |
Lymphoma, B-Cell |
Details
|
| Dual specificity CD19 and CD20 or CD22 CAR-T cell therapy(Chinese PLA General Hospital) |
|
Phase 2 Clinical |
Pla General Hospital |
Lymphoma, B-Cell; Leukemia, B-Cell |
Details
|
| CAR-T-19 Cell Therapy (The General Hospital Of The People'S Liberation Army) |
|
Phase 1 Clinical |
Pla General Hospital |
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Leukemia, B-Cell |
Details
|
| Emfizatamab |
GNC-038 |
Phase 2 Clinical |
Sichuan Baili Pharmaceutical Co Ltd |
Solid tumours; Lymphoma, Large B-Cell, Diffuse; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Extranodal NK-T-Cell; Lymphoma; Lymphoma, Non-Hodgkin; Lymphoma, T-Cell |
Details
|
| Allogenic Anti-CD19 gamma delta CAR-T cell therapy(PLA General Hospital) |
|
Phase 2 Clinical |
Pla General Hospital |
Lymphoma, Non-Hodgkin |
Details
|
| CD19-CAR（The University Of Texas MD Anderson Cancer Center） |
|
Phase 1 Clinical |
The University Of Texas MD Anderson Cancer Center |
Leukemia; Lymphoma |
Details
|
| Inaticabtagene Autoleucel |
CNCT19; CNCT-19; HY001 |
Phase 2 Clinical |
Juventas Cell Therapy Ltd |
Hematologic Neoplasms; Lymphoma, B-Cell; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Non-Hodgkin |
Details
|
| CD19CAR（City Of Hope National Medical Center） |
|
Phase 1 Clinical |
City Of Hope National Medical Center, National Cancer Institute |
Lymphoma, B-Cell; Leukemia, Hairy Cell; Lymphomatoid Granulomatosis; Central Nervous System Neoplasms; Lymphoma; Lymphoma, Non-Hodgkin; Leukemia, Lymphocytic, Chronic, B-Cell |
Details
|
| CD19-CART（Hrain） |
|
Phase 2 Clinical |
Hrain Biotechnology Co Ltd |
Lymphoma, Large B-Cell, Diffuse; Multiple Myeloma; Lymphoma, Follicular; Lymphoma, Mantle-Cell; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma; Lymphoma, Non-Hodgkin; Leukemia, Lymphocytic, Chronic, B-Cell |
Details
|
| AMG-562 |
AMG-562 |
Phase 1 Clinical |
Amgen Inc |
Lymphoma, Large B-Cell, Diffuse; Lymphoma, Mantle-Cell; Lymphoma, Follicular |
Details
|
| GC007g |
GC-007G |
Phase 2 Clinical |
Gracell Biotechnologies (Shanghai) Co Ltd |
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Leukemia, B-Cell |
Details
|
A-Z
